Efficacy and safety of heat-killed Mycobacterium w in Gram-negative sepsis: Prospective study of intravenous administration.
作者信息
Mehta Yatin, Mehta Chitra, Kumar Ashish, Chandrashekar S, George Joby V
机构信息
Medanta Institute of Critical Care and Anesthesia, Medanta The Medicity, Gurugram, Haryana, India.
出版信息
Lung India. 2023 Nov-Dec;40(6):568-571. doi: 10.4103/lungindia.lungindia_298_23.
Abstract
摘要
相似文献
1
Efficacy and safety of heat-killed Mycobacterium w in Gram-negative sepsis: Prospective study of intravenous administration.
Lung India. 2023 Nov-Dec;40(6):568-571. doi: 10.4103/lungindia.lungindia_298_23.
2
Efficacy and Safety of Injection Sepsivac® (Heat-killed Mycobacterium W) in Gram-negative Sepsis administered via an Intravenous Route.
J Assoc Physicians India. 2023 May;71(5):11-12. doi: 10.5005/japi-11001-0221.
3
Retrospective Cohort Observational Study to compare the Effect of Mycobacterium w along with Standard of Care vs Standard of Care alone in critically ill COVID-19 Patients.
J Assoc Physicians India. 2022 Jul;70(7):11-12. doi: 10.5005/japi-11001-0044.
4
A Randomized Trial of Mycobacterium w in Severe Presumed Gram-Negative Sepsis.
Chest. 2021 Oct;160(4):1282-1291. doi: 10.1016/j.chest.2021.03.062. Epub 2021 May 7.
5
Immunogenicity and protective efficacy of "Mycobacterium w" against Mycobacterium tuberculosis in mice immunized with live versus heat-killed M. w by the aerosol or parenteral route.
Infect Immun. 2009 Jan;77(1):223-31. doi: 10.1128/IAI.00526-08. Epub 2008 Nov 3.
6
(MIP) Vaccine: Pharmacology, Indication, Dosing Schedules, Administration, and Side Effects in Clinical Practice.
Indian Dermatol Online J. 2023 Oct 17;14(6):753-761. doi: 10.4103/idoj.idoj_360_23. eCollection 2023 Nov-Dec.
7
A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group.
Crit Care Med. 1995 Jun;23(6):994-1006. doi: 10.1097/00003246-199506000-00003.
8
Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group.
N Engl J Med. 1991 Feb 14;324(7):429-36. doi: 10.1056/NEJM199102143240701.
9
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
Lancet Infect Dis. 2021 Feb;21(2):226-240. doi: 10.1016/S1473-3099(20)30796-9. Epub 2020 Oct 12.
10
Molecular characterization of the acute inflammatory response to infections with gram-negative versus gram-positive bacteria.
Infect Immun. 2003 Oct;71(10):5803-13. doi: 10.1128/IAI.71.10.5803-5813.2003.
引用本文的文献
1
promising immunotherapeutic intervention for diseases.
Front Immunol. 2024 Oct 29;15:1450118. doi: 10.3389/fimmu.2024.1450118. eCollection 2024.
本文引用的文献
1
Efficacy and Safety of Injection Sepsivac® (Heat-killed Mycobacterium W) in Gram-negative Sepsis administered via an Intravenous Route.
J Assoc Physicians India. 2023 May;71(5):11-12. doi: 10.5005/japi-11001-0221.
2
Early Experience of High-dose Intravenous in Critically Ill Patients of COVID-19.
Indian J Crit Care Med. 2021 Sep;25(9):1066-1068. doi: 10.5005/jp-journals-10071-23963.
3
Intensive Care in India in 2018-2019: The Second Indian Intensive Care Case Mix and Practice Patterns Study.
Indian J Crit Care Med. 2021 Oct;25(10):1093-1107. doi: 10.5005/jp-journals-10071-23965.
4
A Randomized Trial of Mycobacterium w in Severe Presumed Gram-Negative Sepsis.
Chest. 2021 Oct;160(4):1282-1291. doi: 10.1016/j.chest.2021.03.062. Epub 2021 May 7.
5
Why Septic Patients Remain Sick After Hospital Discharge?
Front Immunol. 2021 Feb 15;11:605666. doi: 10.3389/fimmu.2020.605666. eCollection 2020.
6
TLR9 and COVID-19: A Multidisciplinary Theory of a Multifaceted Therapeutic Target.
Front Pharmacol. 2021 Jan 15;11:601685. doi: 10.3389/fphar.2020.601685. eCollection 2020.
7
Efficacy and Safety of Mycobacterium indicus pranii as an adjunct therapy in Category II pulmonary tuberculosis in a randomized trial.
Sci Rep. 2017 Jun 13;7(1):3354. doi: 10.1038/s41598-017-03514-1.
8
A randomized trial of TLR-2 agonist CADI-05 targeting desmocollin-3 for advanced non-small-cell lung cancer.
Ann Oncol. 2017 Feb 1;28(2):298-304. doi: 10.1093/annonc/mdw608.
9
A randomized trial of Mycobacterium w in severe sepsis.
J Crit Care. 2015 Feb;30(1):85-9. doi: 10.1016/j.jcrc.2014.08.012. Epub 2014 Aug 28.
10
Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis.
N Engl J Med. 2014 Sep 18;371(12):1121-30. doi: 10.1056/NEJMoa1407380. Epub 2014 Sep 1.
Zotero 插件